Optimizing combination treatment in the management of type 2 diabetes

Vascular Health and Risk Management

Volumn 3, Issue 5, 2007, Pages 665-671

  Derosa, Giuseppe ^a   Sibilla, Salvadeo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Cardiovascular risk factors; Combination therapy; Type 2 diabetes

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; DIURETIC AGENT; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIMEPIRIDE PLUS ROSIGLITAZONE; GLIPIZIDE; GLITAZONE DERIVATIVE; INSULIN; INSULIN GLARGINE; INSULIN SENSITIZING AGENT; ISOPHANE INSULIN; LONG ACTING INSULIN; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; MIGLITOL; MITIGLINIDE DERIVATIVE; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; SULFONYLUREA DERIVATIVE; TROGLITAZONE; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETIC ANGIOPATHY; DIABETIC HYPERTENSION; DIET RESTRICTION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; EVIDENCE BASED MEDICINE; FLUID RETENTION; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; HYPOGLYCEMIA; INFLAMMATION; INSULIN HYPOGLYCEMIA; LIFESTYLE MODIFICATION; LIVER TOXICITY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPERGLYCEMIA; RISK FACTORS;

EID: 36148989501     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. American Diabetes Association. 2006. Standards in medical care in diabetes. Diabetes Care, 29(Suppl 1), S4-42.
2. Bailey CJ. 2005. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab, 7(6):675-91.
3. Campbell IW. 2005. The clinical significance of PPAR gamma agonism. Current molecular medicine, 5:349-63.
4. Campia U, Matuskey LA, Panza JA. 2006. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation, 113:867-75.
5. Castaneda C. 2003. Diabetes control with physical activity and exercise. Nutr Clin Care, 6:89-96.
6. De Feo P, Di Loreto C, Ranchelli A, et al. 2006. Exercise and diabetes. Acta Biomed, 77(Suppl 1):14-17.
7. Derosa G, Cicero AFG, Gaddi A, et al. 2004. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Clin Ther, 2:744-54.
8. Derosa G, Gaddi AV, Picinni MN, et al. 2005. Antithrombotic effects of rosiglitazone-metfromin vs glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome). Pharmacotherapy, 637-45.
9. Derosa G, Cicero AF, Gaddi AV, et al. 2005. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. Clin Ther, 27:1383-91.
10. Derosa G, Cicero AF, Gaddi A, et al. 2005. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract, 69:5-13.
11. Derosa G, Gaddi AV, Ciccarelli L, et al. 2005. Long-term effects of glimepiride and rosiglitazone on non-conventionall cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomised, double-blind clinical trial. J Int Med Res, 33:284-94.
12. Derosa G, D'Angelo A, Ragonesi PD, et al. 2007. Metabolic effect of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Intern Med J, 37:79-86.
13. Dormandy A, Charbonell B, Eckland DAJ, et al. 2005. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial macroVascular Events): a randomised control trial. Lancet, 366:1279-89.
14. Evans JM, Ogston SA, Emslie-Smith A, et al. 2006. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia, 49:930-6.
15. Fonseca V. 2003. Effect of thiazolidinediones on body weight in patients with type 2 diabetes mellitus. Am J Med, 115:42S-48S.
16. Golay A, Ybarra J. 2005. Link between obesity and type 2 diabetes. Best Pract Res Clin Endocrinol Metab, 19:649-63.
17. Hanefeld M, Brunetti P, Schernthaner GH, et al. 2004. One-year glycemic control with a sulphonylurea plus pioglitazone versus a sulphonylurea plus metformin in patients with type 2 diabetes. Diabetes Care, 27:141-7.
18. Hundal RS, Inzucchi SE. 2003. Metformin: new understandings, new uses. Drugs, 63:1879-94.
19. Hussein Z, Wentworth JM, Nankervis AJ, et al. 2004. Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital. Med J Aust, 181:326.
20. Inzucchi SE. 2002. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA, 287:360-72.
21. Jokl R, Laimins M, Klein RL, et al. 1994. Platelet plasminogen activator inhibitor 1 in patients with type II diabetes. Diabetes Care, 17:818-23.
22. Krentz AJ, Bailey CJ. 2005. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs, 65:385-411.
23. Lawrence JM, Reid J, Taylor GJ, et al. 2004. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care, 27:41-6.
24. Mudaliar S, Chang AR, Henry RR. 2003. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract, 9:406-16.
25. Negro R, Dazzi D, Hassan H, et al. 2004. Pioglitazone reduces blood pressure in non-dipping diabetic patients. Minerva Endocrinol, 29:11-17.
26. Nesto RW, Bell D, Bonow R, et al. 2004. Consensus Statement Thiazolidinedione Use, fluid retention and congestive heart failure. Diabetes Care, 27:256-62.
27. Petri A, de Lusignan S, Williams J, et al. 2006. Management of cardiovascular risk factors in people with diabetes in primary care: Cross-sectional study. Public Health, 120:654-63.
28. Pfutzner A, Schondorf T, Seidel D, et al. 2006. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. Metabolism, 55:20-5.
29. Rendell M. 2004. The role of sulphonylureas in the management of type diabetes mellitus. Drugs, 64:1339-58.
30. Riveline JP, Danchin N, Ledru F, et al. 2003. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. Diabetes Metab, 29:207-22.
31. Roberts AW, Thomas A, Rees A, et al. 2003. Peroxisome proliferator-activated receptors-γ agonists in atherosclerosis: current evidence and future directions. Curr Opinion Lipidol, 14:567-73.
32. Samaha FF, Szapary PO, Iqbal N, et al. 2006. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol, 26:1413-14.
33. Schnell O, Standl E. 2006. Impaired glucose tolerance, diabetes, and cardiovascular disease. Endocr Pract, 12(Suppl 1):16-19.
34. Tiikkainen M, Hakkinen AM, Korsheninnikova E, et al. 2004. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes, 53:2169-76.
35. Turner RC, Cull CA, Frighi V, et al. 1999. Glycemic control with diet sulphonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospectives Diabetes Study (UKPDS) Group. JAMA, 281:2005-012.
36. Vaag AA. 2006. Glycemic control and prevention of microvascular and macrovascular disease in the Steno 2 study. Endocr Pract, 12(Suppl 1):89-92.
37. Verges B. 2004 Clinical interest of PPARs ligands. Diabetes Metab, 30:7-12.
38. Weissman PN, Goldstein BJ, Campbell JC, et al. 2004. Rosiglitazone plus metformin combination effects on cardiovasula risk markers suggest potential cardiovascular benefits in type 2 diabetic patients (abstract n.121-OR) Diabetes, Suppl 2:28.
39. Ziegler D. 2005. Type 2 diabetes as an inflammatory cardiovascular disorder. Curr Mol Med, 5:309-22.